The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies

被引:15
作者
Calik, Sebnem [1 ]
Ari, Alpay [1 ]
Bilgir, Oktay [2 ]
Cetintepe, Tugba [2 ]
Yis, Reyhan [3 ]
Sonmez, Ufuk [1 ]
Tosun, Selma [1 ]
机构
[1] Univ Hlth Sci, Izmir Bozyaka Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Izmir, Turkey
[2] Univ Hlth Sci, Dept Hematol, Izmir, Turkey
[3] Univ Hlth Sci, Dept Microbiol & Clin Microbiol, Izmir, Turkey
关键词
BLOOD-STREAM INFECTIONS; CANCER; MANAGEMENT; FEVER; EPIDEMIOLOGY; COMBINATION; GUIDELINES; AMIKACIN; THERAPY; TRIAL;
D O I
10.15537/smj.2018.9.22824
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To determine effective risk factors on mortality in febrile neutropenic cases with hematologic malignancy. Patients with hematologic diseases are more prone to infections and those are frequent causes of mortality. Methods: This retrospective study was performed using data of 164 febrile neutropenic cases with hematologic malignancies who were followed up in a hematology clinic of a tertiary health care center between 2011-2015. The relationship between descriptive and clinical parameters rates and rates of mortality on the 7th and the 21st days were investigated. Results: Patients with absolute neutrophil count<100/mm(3), duration of neutropenia longer than 7 days, pneumonia or gastrointestinal foci of infection, central catheterization (p=0.025), isolation of Gram (-) bacteria in culture, carbapenem resistance, septic shock, and bacterial growth during intravenous administration of antibiotic treatment were under more risk for mortality on both the 7th and the 21st days. The final multivariate logistic regression results showed that pneumonia (p<0.0001), septic shock (p=0.004) and isolation of Gram-negative bacteria (p=0.032) were statistically significant risk factors. Conclusion: Early diagnosis and appropriate treatment of serious infections, which are important causes of morbidity and mortality, are crucial in patients with febrile neutropenia. Thus, each center should closely follow up causes of infection and establish their empirical antibiotherapy protocols to accomplish better results in the management of febrile neutropenia.
引用
收藏
页码:878 / 885
页数:8
相关论文
共 23 条
  • [1] A European organization for Research and Treatment of Cancer - International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer
    Akova, M
    Paesmans, M
    Calandra, T
    Viscoli, C
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) : 239 - 245
  • [2] The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit
    Cornejo-Juarez, P.
    Vilar-Compte, D.
    Perez-Jimenez, C.
    Namendys-Silva, S. A.
    Sandoval-Hernandez, S.
    Volkow-Fernandez, P.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 31 : 31 - 34
  • [3] Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: Microbiological, clinical and economic evaluation
    D'Antonio, D
    Staniscia, T
    Piccolomini, R
    Fioritoni, G
    Rotolo, S
    Parruti, G
    Di Bonaventura, G
    Manna, A
    Savini, V
    Fiorilli, MP
    Di Giovanni, P
    Francione, A
    Schioppa, F
    Romano, F
    [J]. CHEMOTHERAPY, 2004, 50 (02) : 81 - 87
  • [4] Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
    Forcina, Alessandra
    Lorentino, Francesca
    Marasco, Vincenzo
    Oltolini, Chiara
    Marcatti, Magda
    Greco, Raffaella
    Lupo-Stanghellini, Maria Teresa
    Carrabba, Matteo
    Bernardi, Massimo
    Peccatori, Jacopo
    Corti, Consuelo
    Ciceri, Fabio
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1476 - 1482
  • [5] Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?
    Gedik, Habip
    Simsek, Funda
    Kanturk, Arzu
    Yildirmak, Taner
    Arica, Deniz
    Aydin, Demet
    Demirel, Naciye
    Yokus, Osman
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 743 - 752
  • [6] Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer
    Ha, Young Eun
    Kang, Cheol-In
    Cha, Min Kyeong
    Park, So Yeon
    Wi, Yu Mi
    Chung, Doo Ryeon
    Peck, Kyong Ran
    Lee, Nam Yong
    Song, Jae-Hoon
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (05) : 403 - 409
  • [7] 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
    Hughes, WT
    Armstrong, D
    Bodey, GP
    Bow, EJ
    Brown, AE
    Calandra, T
    Feld, R
    Pizzo, PA
    Rolston, KVI
    Shenep, JL
    Young, LS
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) : 730 - 751
  • [8] Infectious Diseases Society of Taiwan, 2005, J Microbiol Immunol Infect, V38, P455
  • [9] Jarque Isidro, 2005, Enferm Infecc Microbiol Clin, V23 Suppl 5, P24, DOI 10.1157/13091243
  • [10] Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy
    Kang, Cheol-In
    Chung, Doo Ryeon
    Ko, Kwan Soo
    Peck, Kyong Ran
    Song, Jae-Hoon
    [J]. ANNALS OF HEMATOLOGY, 2012, 91 (01) : 115 - 121